Browsing Tag
biotech financing
9 posts
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.
Why Inhibikase Therapeutics (NASDAQ: IKT) is tapping public markets now for $100m in new funding
Find out how Inhibikase Therapeutics plans to use its $100M equity raise to fund pipeline trials and what it means for shareholders in 2025.
BioHarvest Sciences completes nearly $20m financing round — what it means for shareholders and future growth
Find out how BioHarvest Sciences’ $19.9 million public offering is shaping its expansion plans, investor sentiment, and biotech growth outlook today.
Precision BioSciences $75m stock and warrant offering sparks debate over biotech funding momentum
Precision BioSciences completes a $75 million stock and warrant offering to fund its ARCUS gene-editing pipeline — find out how this move reflects broader biotech funding trends.
Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12
Palatin Technologies regains NYSE American compliance and secures $15.8M for its oral MC4R obesity drug. Find out how the relisting and IND impact its biotech trajectory.
Savara’s $130m stock offering strengthens cash position ahead of MOLBREEVI launch
Savara raises $130 million through stock and warrant sale to fund MOLBREEVI’s rare-disease launch—find out how this deal reshapes its commercialization path.
Inside Vivani Medical’s $15.7m equity raise and what the $1.62 pricing reveals about market sentiment
Find out how Vivani Medical’s $15.7 million stock sale at $1.62 a share could reshape its funding strategy and investor sentiment.
Rani Therapeutics seals $1.085bn Chugai deal and $60m oversubscribed financing to fuel oral biologics push
Rani Therapeutics secured a $1.085 B Chugai collaboration and an oversubscribed $60.3 M raise. Find out how this dual deal could redefine its biotech trajectory.
Investors eye KalVista’s $125m debt raise—Can EKTERLY commercialization justify the premium terms?
KalVista raises $125M through convertible notes due 2031 to fund EKTERLY commercialization. Find out what this financing means for biotech investors.